ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022)
ARS Pharmaceuticals' (SPRY) quarterly Long-Term Investments came in at $24.2 million in Q2 2022, down 44.93% quarter-over-quarter from $44.0 million in Q1 2022.
ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022) Analysis & Trends
ARS Pharmaceuticals has disclosed Long-Term Investments across 2 years of filings, most recently posting $24.2 million for Q2 2022.
- Long-Term Investments for Q2 2022 came in at $24.2 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2022 was $24.2 million (changed N/A YoY), and the FY2021 annual result was $64.8 million, changed N/A from the prior year.
- Long-Term Investments came in at $24.2 million for Q2 2022 at ARS Pharmaceuticals, down from $44.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $64.8 million in Q4 2021 to a low of $24.2 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | ARS Pharmaceuticals | 954.24 Mn | 753.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 24.22 Mn |
| Mar 31, 2022 | 43.97 Mn |
| Dec 31, 2021 | 64.78 Mn |
| Sep 30, 2021 | 39.94 Mn |